for your Forsite and more 
GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Nexwise Intelligence China
301248
5
Astro-century Education & Technology
300654
US Stock MarketDetailed Quotes
CNM Core & Main
- 56.860
- -0.400-0.70%
Close Jan 23 16:00 ET
- 56.860
- 0.0000.00%
Post 20:01 ET
10.81BMarket Cap26.57P/E (TTM)
57.500High56.568Low1.25MVolume57.190Open57.260Pre Close71.34MTurnover0.72%Turnover Ratio26.45P/E (Static)190.19MShares62.15052wk High6.47P/B9.87BFloat Cap37.22052wk Low--Dividend TTM173.53MShs Float62.150Historical High--Div YieldTTM1.63%Amplitude18.750Historical Low56.937Avg Price1Lot Size
Core & Main Stock Forum
Sign in to post a comment
After pulling back during the day, the S&P 500 and Nasdaq hit fresh closing highs- and the Nasdaq hit a trading high of 19,486.15.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ climbed 0.05%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.17%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.40%.
MACRO
JOLTS job openings from the Bureau of Labor Statistics came in at 7.74M, higher than last month's number, but ever since Ap...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ climbed 0.05%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.17%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.40%.
MACRO
JOLTS job openings from the Bureau of Labor Statistics came in at 7.74M, higher than last month's number, but ever since Ap...
38
10
8
Core & Main's high P/E ratio is due to investors' anticipation of robust future growth. The company's excellent earnings outlook is driving its high P/E. Investors believe the risk of earnings decline isn't significant enough to warrant a lower P/E ratio.
1
Core & Main's acquisition of Dana Kepner is seen as a chance to broaden its geographic reach, diversify its product and service offerings, and incorporate key talent. The merger is expected to provide the water and wastewater industry with unparalleled service.
1
Gapping up
In reaction to earnings/guidance:
• $Coty Inc (COTY.US)$ +3.9%, $General Mills (GIS.US)$+2.6%
Other news:
• $Clene (CLNN.US)$ +5.3% (announces presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension)
• $Clearway Energy-C (CWEN.US)$ +2.5% (Provides operational update on El Segundo Energy Center)
• $Apartment Income (AIRC.US)$ +2.4% (provides operating update)
• $Alpine Immune (ALPN.US)$ +2.3% (...
In reaction to earnings/guidance:
• $Coty Inc (COTY.US)$ +3.9%, $General Mills (GIS.US)$+2.6%
Other news:
• $Clene (CLNN.US)$ +5.3% (announces presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension)
• $Clearway Energy-C (CWEN.US)$ +2.5% (Provides operational update on El Segundo Energy Center)
• $Apartment Income (AIRC.US)$ +2.4% (provides operating update)
• $Alpine Immune (ALPN.US)$ +2.3% (...
9
1
1
Gapping up
In reaction to earnings/guidance:
• $Bowlero (BOWL.US)$ +3.4%
Other news:
• $Intellia Therapeutics (NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc (GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics (ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
In reaction to earnings/guidance:
• $Bowlero (BOWL.US)$ +3.4%
Other news:
• $Intellia Therapeutics (NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc (GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics (ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
13
1
Gapping up
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...
10
3
Gainers:
• $National Vision (EYE.US)$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze (BRZE.US)$ +12.2% (In reaction to earnings/guidance)
• $Oracle (ORCL.US)$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf (WULF.US)$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources (CLR.US)$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
• $National Vision (EYE.US)$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze (BRZE.US)$ +12.2% (In reaction to earnings/guidance)
• $Oracle (ORCL.US)$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf (WULF.US)$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $Continental Resources (CLR.US)$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
8
6
5
Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
14
1
No comment yet
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
U.S.-China talks spark interest, no more inflation?
🎙️Discussion: 1. How will Trump's China policies affect Chinese assets? 2. Which sectors might benefit as U.S. inflation risks decline?
Moomoo News Global
Dec 9, 2024 20:23
China Will Adopt a "Moderately Accommodative" Monetary Policy in the Next Year, The First Shift to Easing Since 2011
Clement Lemons : okk
章允量 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
103575541 :
RetireWise : Ho ho ho... Santa Claus is coming to town
Adrianlim90 : 1
View more comments...